These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27719716)

  • 1. [Efficacy of GLIDE chemotherapy for patients with newly diagnosed advanced-stage or relapsed/refractory extranodal natural killer cell lymphoma].
    Ji J; Xiang B; Liu ZG; Jia YQ; Zhu HL; Niu T; Pan L; Chang H; Huang J; Wu Y; Li JJ; He C; Ma HB; Tang Y; Dong T; Liu T
    Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):751-755. PubMed ID: 27719716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.
    Zhou Z; Li X; Chen C; Li X; Zhang L; Li L; Wang X; Ma W; Fu X; Wu J; Sun Z; Zhang X; Li Z; Yan J; Chang Y; Lu L; Qin B; Li X; Wen J; Zhang M
    Ann Hematol; 2014 Nov; 93(11):1889-94. PubMed ID: 24923454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.
    Li X; Cui Y; Sun Z; Zhang L; Li L; Wang X; Wu J; Fu X; Ma W; Zhang X; Chang Y; Nan F; Li W; Su L; Wang J; Xue H; Zhang M
    Clin Cancer Res; 2016 Nov; 22(21):5223-5228. PubMed ID: 27060152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type.
    Ji J; Liu T; Xiang B; Liu W; He C; Chen X; Li J; Chang H; Dai Y; Dong T
    Leuk Lymphoma; 2014 Dec; 55(12):2955-7. PubMed ID: 24679007
    [No Abstract]   [Full Text] [Related]  

  • 5. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
    Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
    Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study.
    Wei C; Cao X; Zhang W; Zhang Y; Wang W; Zhang L; Yang C; Feng J; Cai H; Chen M; Mao Y; Zhou D
    Ann Hematol; 2020 Dec; 99(12):2801-2809. PubMed ID: 32399707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
    Yamaguchi M; Suzuki R; Kwong YL; Kim WS; Hasegawa Y; Izutsu K; Suzumiya J; Okamura T; Nakamura S; Kawa K; Oshimi K
    Cancer Sci; 2008 May; 99(5):1016-20. PubMed ID: 18294294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
    Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G
    Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the clinical efficacies of two L-asparaginase-based chemotherapy regimens for newly diagnosed nasal-type extranodal NK/T-cell lymphoma.
    Wu W; Ren K; Chen X; Li N; Luo Q; Hai T; Zhou H; Zou L
    Cancer Med; 2023 Apr; 12(8):9458-9470. PubMed ID: 37000008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
    Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
    Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes.
    Brammer JE; Chihara D; Poon LM; Caimi P; de Lima M; Ledesma C; Rondon G; Ciurea SO; Nieto Y; Fanale M; Dabaja B; Maziarz RT; Champlin RE; Hosing C; Oki Y
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e41-e50. PubMed ID: 29277360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients.
    Kim SJ; Park S; Kang ES; Choi JY; Lim DH; Ko YH; Kim WS
    Ann Hematol; 2015 Jan; 94(1):71-8. PubMed ID: 25082384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149.
    Zhang L; Jia S; Ma Y; Li L; Li X; Wang X; Fu X; Ma W; Qin Y; Li W; Wu J; Sun Z; Zhang X; Nan F; Chang Y; Li Z; Zhang D; Wang G; Yan J; Su L; Wang J; Xue H; Young KH; Zhang M
    Oncotarget; 2016 Aug; 7(34):55721-55731. PubMed ID: 27384676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment and Prognosis of Newly Diagnosed Advanced-Stage Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Real-World Study across Two Decades.
    Wei YC; Qi F; Chen B; Zhang CG; Fang H; Zhang D; Qi SN; Chai Y; Li YX; Dong M
    Chemotherapy; 2024; 69(2):108-121. PubMed ID: 37984344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial.
    Wang X; Zhang L; Liu X; Li X; Li L; Fu X; Sun Z; Wu J; Zhang X; Yan J; Chang Y; Nan F; Zhou Z; Wu X; Tian L; Ma M; Li Z; Yu H; Zhu L; Wang Y; Shi C; Feng X; Li J; Ding M; Zhang J; Dong M; Xue H; Wang J; Zou L; Su L; Wu J; Liu L; Bao H; Zhang L; Guo Y; Guo S; Lu Y; Young KH; Li W; Zhang M
    JAMA Oncol; 2022 Jul; 8(7):1035-1041. PubMed ID: 35708709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
    Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X
    Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
    Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
    J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study.
    Wang H; Wuxiao ZJ; Zhu J; Wang Z; Wang KF; Li S; Chen X; Lu Y; Xia ZJ
    Leuk Lymphoma; 2015 Apr; 56(4):971-7. PubMed ID: 24991715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report.
    Liu YC; Lin TA; Wang HY; Ko PS; Liu CJ; Hsiao LT; Chien SH; Gau JP
    J Med Case Rep; 2020 Mar; 14(1):43. PubMed ID: 32183896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
    Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
    Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.